Evidence map›Paper›PMID 42664253›Full record

ArticlePloS one2026

Genotype distribution of high-risk and potential high-risk HPV types among women in different screening and clinic settings in Ghana and Kenya.

Eliza Mari Kwesi-Maliepaard, Judith A Osea-Larbi, Celestine K Nyamari, Yakubu Alhassan, Adelaide K Sromani, Vera M Kotey, Stephanie Darko, Randy Tackie, Ruth Kiome, Aisha M Mohammed and 20 more

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

30 authors.

Eliza Mari Kwesi-MaliepaardYemaachi Biotech Ltd, Accra, Ghana.ORCID https://orcid.org/0000-0001-9658-1935
Judith A Osea-LarbiWest African Genetic Medicine Centre, University of Ghana, Accra, Ghana.
Celestine K NyamariYemaachi Biotech Ltd, Accra, Ghana.
Yakubu AlhassanYemaachi Biotech Ltd, Accra, Ghana.
Adelaide K SromaniYemaachi Biotech Ltd, Accra, Ghana.
Vera M KoteyYemaachi Biotech Ltd, Accra, Ghana.
Stephanie DarkoYemaachi Biotech Ltd, Accra, Ghana.
Randy TackieYemaachi Biotech Ltd, Accra, Ghana.
Ruth KiomeYemaachi Biotech Ltd, Accra, Ghana.
Aisha M MohammedYemaachi Biotech Ltd, Accra, Ghana.
Erica BuadiiYemaachi Biotech Ltd, Accra, Ghana.
Emmanuel K QuayeYemaachi Biotech Ltd, Accra, Ghana.
Harry AkligohYemaachi Biotech Ltd, Accra, Ghana.
Barikisu A IbrahimYemaachi Biotech Ltd, Accra, Ghana.ORCID https://orcid.org/0000-0001-6792-9410
Patricia KabaYemaachi Biotech Ltd, Accra, Ghana.
Susan Florence AmoakoYemaachi Biotech Ltd, Accra, Ghana.
Esmy KoteyYemaachi Biotech Ltd, Accra, Ghana.
Seth AgyemangYemaachi Biotech Ltd, Accra, Ghana.
Joyce M NgoiYemaachi Biotech Ltd, Accra, Ghana.
Lily PaemkaYemaachi Biotech Ltd, Accra, Ghana.
Kwaku DarkwaSanford World Clinic, Mankessim, Ghana.
Thywill DegleySanford World Clinic, Mankessim, Ghana.
Nathan Edward SiebuWest African Genetic Medicine Centre, University of Ghana, Accra, Ghana.
Charles Ochieng' OlwalYemaachi Biotech Ltd, Accra, Ghana.ORCID https://orcid.org/0000-0003-1747-2963
Collins M Morang'aYemaachi Biotech Ltd, Accra, Ghana.
Aida ManuYemaachi Biotech Ltd, Accra, Ghana.
David HutchfulYemaachi Biotech Ltd, Accra, Ghana.ORCID https://orcid.org/0000-0002-3646-1736
Emmanuella AmoakoYemaachi Biotech Ltd, Accra, Ghana.ORCID https://orcid.org/0000-0002-2965-7597
Frank G OnyambuYemaachi Biotech Ltd, Accra, Ghana.ORCID https://orcid.org/0000-0002-1195-8762
Yaw BediakoYemaachi Biotech Ltd, Accra, Ghana.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe burden of cervical cancer is highest in Africa. Human papillomavirus (HPV) infection is the major cause of cervical cancer. There are over 200 different HPV genotypes, with 15 considered (potential) high-risk genotypes for developing cancer. Due to a lack of systematic screening programs in most African countries, there is limited data available on the most prevalent HPV genotypes in the population. This study aimed to assess the prevalence and distribution of HPV genotypes in cohorts in Ghana and Kenya.

methodsWe analyzed HPV genotyping data from cervical samples submitted for diagnostic HPV genotype testing between July 2022 and March 2025. Our database contained results from samples obtained from outreach screening events in Accra, the capital of Ghana (n = 680), a research project in Ghana outside of Accra (n = 426), clinician-collected samples submitted through clinics in Ghana (n = 118), samples from participants in Ghana who independently sought HPV genotyping through community-based providers, pharmacies, clinics, or online testing services outside organized screening programmes (n = 181) and samples from an outreach screening event in Kenya (n = 46). All samples were from women 18 years old and above. Positivity for HPV genotypes (HPV-16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68) was determined by RT-PCR, using the AmpFire HPV High Risk Genotyping kit.

resultsHPV positivity in the Ghana screening group was 34.9%, with multiple genotypes detected in 39.2% of the positive cases. The main HPV genotype in the Ghana screening group was HPV-39 (19.0%), which was especially prevalent in the younger age group (<30 years), followed by HPV-53 (15.2%) and HPV-68 (15.2%). HPV infection (Odds Ratio (OR) 3.09, Confidence Interval (CI) 1.92-4.97, p < 0.001) and infection with multiple genotypes (OR 3.45, CI 1.42-8.38, p = 0.006) was associated with younger age in the Ghana screening group. In the Ghana research group HPV-53 was the most common genotype (18.9%), followed by HPV-39 (18.0%). In the clinician-collected group HPV-16 (18.6%) was the most common genotype. In the self-collected samples from participants who independently sought HPV testing HPV-39 (17.9%) and HPV-51 (17.9%) were the most common genotypes. In the much smaller Kenya screening group HPV-51 (46.2%) was the most prevalent genotype.

conclusionsOur study shows HPV genotype distribution in different settings. This emphasizes the importance of systematic population-wide HPV screening to understand local HPV infections patterns.

Indexed as

Human Papillomavirus VirusesPapillomaviridaePapillomavirus InfectionsUterine Cervical NeoplasmsAdolescentAdultEarly Detection of CancerFemaleGenotypeGhanaHumansKenyaMass ScreeningMiddle AgedPrevalenceYoung Adult

Identifiers

PMID42664253
PMCPMC13524295

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.